Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-07-01
2008-07-01
Hartley, Michael G. (Department: 1618)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07393863
ABSTRACT:
Methods of treating, preventing and/or managing myelodysplastic syndromes are disclosed. Specific methods encompass the administration of an immunomodulatory compound, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active ingredient, and/or the transplantation of blood or cells. Specific second active ingredients are capable of affecting or blood cell production. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
REFERENCES:
patent: 3536809 (1970-10-01), Applezweig
patent: 3598123 (1971-08-01), Zaffaroni
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 3916899 (1975-11-01), Theeuwes et al.
patent: 4008719 (1977-02-01), Theeuwes et al.
patent: 4810643 (1989-03-01), Souza
patent: 4999291 (1991-03-01), Souza
patent: 5059595 (1991-10-01), LeGrazie
patent: 5073543 (1991-12-01), Marshall et al.
patent: 5120548 (1992-06-01), McClelland et al.
patent: 5134127 (1992-07-01), Stella et al.
patent: 5229496 (1993-07-01), Deeley et al.
patent: 5288487 (1994-02-01), Kawashima et al.
patent: 5354556 (1994-10-01), Sparks et al.
patent: 5385901 (1995-01-01), Kaplan et al.
patent: 5391485 (1995-02-01), Deeley et al.
patent: 5393870 (1995-02-01), Deeley et al.
patent: 5528823 (1996-06-01), Rudy et al.
patent: 5580755 (1996-12-01), Souza
patent: 5591767 (1997-01-01), Mohr et al.
patent: 5593990 (1997-01-01), D'Amato
patent: 5629327 (1997-05-01), D'Amato
patent: 5635517 (1997-06-01), Muller et al.
patent: 5639476 (1997-06-01), Oshlack et al.
patent: 5643915 (1997-07-01), Andrulis et al.
patent: 5674533 (1997-10-01), Santus et al.
patent: 5698579 (1997-12-01), Muller
patent: 5712291 (1998-01-01), D'Amato
patent: 5733566 (1998-03-01), Lewis
patent: 5798368 (1998-08-01), Muller et al.
patent: 5874448 (1999-02-01), Muller et al.
patent: 5877200 (1999-03-01), Muller
patent: 5929117 (1999-07-01), Muller et al.
patent: 5955476 (1999-09-01), Muller et al.
patent: 6011050 (2000-01-01), Muller et al.
patent: 6071948 (2000-06-01), D'Amato
patent: 6096757 (2000-08-01), Bishop et al.
patent: 6228879 (2001-05-01), Green et al.
patent: 6281230 (2001-08-01), Muller et al.
patent: 6316471 (2001-11-01), Muller et al.
patent: 6335349 (2002-01-01), Muller et al.
patent: 6380239 (2002-04-01), Muller et al.
patent: 6395754 (2002-05-01), Muller et al.
patent: 6403613 (2002-06-01), Man et al.
patent: 6420414 (2002-07-01), D'Amato
patent: 6458810 (2002-10-01), Muller et al.
patent: 6469045 (2002-10-01), D'Amato
patent: 6476052 (2002-11-01), Muller et al.
patent: 6518298 (2003-02-01), Green et al.
patent: 6673828 (2004-01-01), Green et al.
patent: 2001/0021380 (2001-09-01), Pluenneke
patent: 2001/0056114 (2001-12-01), D'Amato
patent: 2002/0035090 (2002-03-01), Zeldis et al.
patent: 2002/0045643 (2002-04-01), Muller et al.
patent: 2002/0052398 (2002-05-01), D'Amato
patent: 2002/0054899 (2002-05-01), Zeldis
patent: 2002/0061923 (2002-05-01), D'Amato
patent: 2002/0161023 (2002-10-01), D'Amato
patent: 2002/0173658 (2002-11-01), Muller et al.
patent: 2002/0183360 (2002-12-01), Muller et al.
patent: 2003/0028028 (2003-02-01), Man et al.
patent: 2003/0045552 (2003-03-01), Robarge et al.
patent: 2003/0069428 (2003-04-01), Muller et al.
patent: 2003/0096841 (2003-05-01), Robarge et al.
patent: 2003/0139451 (2003-07-01), Shah et al.
patent: 2003/0144325 (2003-07-01), Muller et al.
patent: 2003/0181428 (2003-09-01), Green et al.
patent: 2003/0187024 (2003-10-01), D'Amato
patent: 2003/0191098 (2003-10-01), D'Amato
patent: 2003/0235909 (2003-12-01), Hariri et al.
patent: 2004/0029832 (2004-02-01), Zeldis
patent: 2004/0077685 (2004-04-01), Figg et al.
patent: 2004/0077686 (2004-04-01), Dannenberg et al.
patent: 2004/0087546 (2004-05-01), Zeldis
patent: 2004/0091455 (2004-05-01), Zeldis
patent: 2004/0122052 (2004-06-01), Muller et al.
patent: 11-286455 (1999-10-01), None
patent: WO 98/03502 (1998-01-01), None
patent: WO 98/54170 (1998-12-01), None
patent: WO 01/87306 (2001-11-01), None
patent: WO 01/87307 (2001-11-01), None
patent: WO-02/059106 (2002-08-01), None
patent: WO 02/059106 (2002-08-01), None
patent: PCT/US03/11323 (2003-09-01), None
patent: WO 03/097040 (2003-11-01), None
patent: WO 2005/110085 (2005-11-01), None
Azra Raza et al. Thalidomide Produces Transfusion independence in long-standing refractory anemias of patieints with myelodysplastic syndromes; Blood, 98(4), 958-965, 2002.
U.S. Appl. No. 60/372,348, filed Apr. 12, 2002, Hariri et al.
Beazley et al., 1985, “Malignant stricture at the confluence of the biliary tree: diagnosis and management,”Surg. Annu. 17:125-41.
Bennett et al., 1985, “Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group,”Ann. Intern. Med. 103(4):620-625.
Besa, 1992, “Myelodysplastic syndromes (refractory anemia). A perspective of the biologic, clinical, and therapeutic issues,”Med. Clin. North Am. 76(3):599-617.
Besa et al., 1990, 76(Supp. 1):133a.
Bowen et al., 1991, “The treatment of anaemia in the myelodysplastic syndromes with recombinant human erythropoietin,”Br. J. Haematol. 77(3):419-423.
Cartensen, 1995,Drug Stability: Principles&Practice, 2nd ed., Marcel Dekker, New York, NY pp. 379-380.
Corral et al., 1999,Ann. Rheum. Dis. 58(Supp. I):1107-1113.
Costa et al., 1998,Blood92(10:suppl. 1):235b, Abstract #4007.
D'Amato et al., 1994, “Thalidoide is an inhibitor of angiogenesis,”PNAS USA91(9):4082-4085.
Dexter, 1989, “Haemopoietic growth factors,”Br. Med. Bull. 45(2):337-349.
Dexter, 1987, “Growth factors involved in haemopoiesis.”J. Cell. Sci. 88 ( Pt 1):1-6.
Dredge et al., 2002, “Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects,”Br. J. Cancer87(10):1166-1172.
Ehrenpreis et al., 1999, “Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial,”Gastroenterology117(6):1271-1277.
Emens et al., 2001, “Chemotherapy: friend or foe to cancer vaccines?”Curr. Opin. Mol. Ther. 3(1):77-84.
Golde et al., 1988, “Hormones that stimulate the growth of blood cells,”Sci. Am. 259(1):62-71.
Goldberg et al., 1990, “Survey of exposure to genotoxic agents in primary myelodysplastic syndrome: correlation with chromosome patterns and data on patients without hematological disease,”Cancer Res. 50(21):6876-6881.
Greenberg et al., 1997, “International scoring system for evaluating prognosis in myelodysplastic syndromes,”Blood89(6):2079-2088.
Gupta et al., 2001, “Adherences of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications,”Leukemia15:1950-1961.
Handman et al., 1979, “Stimulation by granulocyte-macrophage colony-stimulating factor ofLeishmania tropicakilling by macrophages,”J. Immunol. 122(3):1134-1137.
Harris et al., 1999, “World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, Nov. 1997,”J. Clin. Oncol. 17(12):3835-3849.
Hellstrom et al., 1990, 76(Supp. 1):279a.
Koch, 1985, “Thalidomide and congeners as anti-inflammatory agents,”Prog. Med. Chem. 22:165-242.
Kropff, 2000,Blood96(11 part 1):168a.
Kurland et al., 1979, “Induction of prostaglandin E synthesis in normal and neoplastic macrophages: role for colony-stimulating factor(s) distinct from effects on myeloid progenitor cell proliferation,”Proc. Natl. Acad. Sci. USA76(5):2326-2330.
Lentzsch et al., 2003, “Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo,”Leukemia17(1):41-44.
List, 2002, ASH Abstract #521.
Marriott et al., 2001, “Immunotherapeutic and antitumor potential of thalidomide analogues,”Ex
Celgene Corporation
Hartley Michael G.
Jones Day
Samala Jagadishwar R
LandOfFree
Methods of using... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of using..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of using... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2789914